Collaborative Modifiers

Protein-protein interactions are important cancer drug targets

Protein-protein interactions (PPI) play a central role in cancer. PPI form signaling nodes and hubs that transmit pathophysiological cues along molecular networks to achieve an integrated biological output. PPI are at the center of promoting the formation of new tumors and tumor growth and metastasis.

Breakthrough solution to inhibit protein-protein interaction

The Collaborative Modifiers can efficiently inhibit PPI. As small molecules they can easily cross cell membranes and reach cancer PPI targets within cells. 

The first use of the Collaborative Modifiers: Myc inhibition

Myc overexpression is involved in almost all cancers. And Myc  inhibition can disable multiple mechanisms that cancer cells rely on for survival. But over a decade major pharma companies could not develop an efficient inhibitors for Myc.